OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-07-01 to 2025-07-01.)

Article	Citations
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	348
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	219
Regulation of the hippocampal translatome by Apoer2-ICD release	211
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	195
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	192
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	189
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	186
Tau interactome and RNA binding proteins in neurodegenerative diseases	176
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	162
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	161
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	159
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	146
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	146
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	135
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	127
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	127
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	127
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	122
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	117
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	114
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	111
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	96
Sex dependent glial-specific changes in the chromatin accessibility landscape in late-onset Alzheimer’s disease brains	95
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	92
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	91

Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	87
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	86
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	83
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	83
In Memoriam of Edward H. Koo, MD 1954–2025	81
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	73
Combination therapy using GDNF and cell transplant in Parkinson’s disease	70
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	70
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	70
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	68
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	67
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	66
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	66
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	66
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	65
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	63
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	62
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	61
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	60
Using mass spectrometry to validate mouse models of tauopathy	59
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	56
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	56
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	55
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	55
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	53
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	52
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	52
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	52
The endotoxin hypothesis of Alzheimer’s disease	51
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis	51
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	51
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	50
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	50
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	48
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	47
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	47
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	46
Mechanisms of astrocyte aging in reactivity and disease	46
VCP suppresses proteopathic seeding in neurons	46
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	44
SETD7-mediated monomethylation is enriched on soluble Tau in Alzheimer’s disease	44
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery	43
Sex specific molecular networks and key drivers of Alzheimer’s disease	42
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	41
Wild-type FUS corrects ALS-like disease induced by cytoplasmic mutant FUS through autoregulation	41
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	41
SRSF1-dependent inhibition of C9ORF72-repeat RNA nuclear export: genome-wide mechanisms for neuroprotection in amyotrophic lateral sclerosis	40
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	39
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	38
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	38

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans	38
Neuropathology and molecular diagnosis of Synucleinopathies	38
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	37
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	37
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	36
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	36
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	36
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	35
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	35
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	35
The role of inflammasomes in vascular cognitive impairment	35
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	35
MicroRNA-100-5p and microRNA-298-5p released from apoptotic cortical neurons are endogenous Toll-like receptor 7/8 ligands that contribute to neurodegeneration	35
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice	33
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	33
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration	33
Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease	32
Proteo-genomics of soluble TREM2 in cerebrospinal fluid provides novel insights and identifies novel modulators for Alzheimer’s disease	32
Seeding activity of skin misfolded tau as a biomarker for tauopathies	32
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	32
Targeted long-read sequencing to quantify methylation of the C9orf72 repeat expansion	31
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	31
Myelin dysfunction in aging and brain disorders: mechanisms and therapeutic opportunities	31
Early transcriptional and cellular abnormalities in choroid plexus of a mouse model of Alzheimer’s disease	30
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	30
Elevated nuclear TDP-43 induces constitutive exon skipping	30
Microglial ferroptotic stress causes non-cell autonomous neuronal death	30
Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	30
Blood platelet factor 4: the elixir of brain rejuvenation	30